Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
KRISHGEN BIOSYSTEMS Immunoassay for quantitative estimation of Semaglutide in human serum and plasma. Validated against OZEMPIC and local biosimilars for PK studies. Assay Range: 50 - 3000 ng/ml; Sensitivity: 50 ng/ml
Supplier: KRISHGEN BIOSYSTEMS KBI5030
Pack Size: 1 x 96 wells. Introduction: Semaglutide (trade name Ozempic) is a pharmaceutical drug in development by a Danish company Novo Nordisk for the treatment of type 2 diabetes. It is marketed by the name Ozempic. As a glucagon-like peptide-1 receptor agonist, it lowers the blood sugar level by increasing the production of insulin. It was discovered in 2012, by a team of researchers at Novo Nordisk as a longer-acting alternative to liraglutide. This Semaglutide ELISA accurately quantifies semaglutide and biosimilars in human samples. If you are looking to use animal samples, please contact us. ELISA Features include a pre-coated plate with break-apart wells, standardisation and Lot to Lot Consistency with Precision CV <10%.
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?